Palo BioFarma

Focus: Palo BioFarma is a Barcelona-based biotechnology company focused on developing novel drugs targeting adenosine receptors for respiratory and neurological indications. Founded in 2006, the company operates as a focused drug discovery and development organization with a pipeline of early-stage programs.

Respiratory Neurology

Profile data last refreshed 2d ago · AI intelligence enriched 1w ago

Open Jobs

About Palo BioFarma

AI assessmentNot Hiring

No open roles listed right now. Follow Palo BioFarma to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

6 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

PBF-999

Huntington's Disease

Phase 1

Clinical Trials (1)

NCT02208934Study To Assess the Safety and Tolerability of Single Ascending Oral Doses of PBF-999 in Healthy Young Male Volunteers

Phase 1

Help build intelligence for Palo BioFarma

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Specialized expertise in adenosine receptor modulation—a differentiated mechanism with applications in high-unmet-need areas like Huntington's and Parkinson's disease
18-year operational history (founded 2006) provides organizational stability unusual for early-stage biotechs
Dual therapeutic focus on respiratory and neurology allows cross-functional learning across two major disease areas

Watch Out For

Zero open job postings and undisclosed employee count suggest minimal active hiring or possible scaling constraints
All programs remain in Phase 1-2 with no Phase 3 data, meaning 5-10+ year timelines before any potential clinical validation or revenue inflection
No disclosed funding, financial data, or public market presence limits visibility into cash runway, burn rate, or long-term viability

Generated by Claude from Palo BioFarma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

PBF-509

Parkinson Disease

Phase 1

Clinical Trials (1)

NCT02111330Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of PBF -509 (80 mg, 160 mg and 240 mg) "After Multiple Oral Doses" in Healthy Volunteers

Phase 1

PBF-509

Parkinson Disease

Phase 1

Clinical Trials (1)

NCT01691924Study To Assess the Safety and Tolerability of PBF-509 in Male Healthy Volunteers

Phase 1

PBF-680

Asthma

Phase 1

Clinical Trials (1)

NCT02208973Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of PBF-680 After Multiple Oral Doses"

Phase 1

PBF-680

Asthma

Phase 1

Clinical Trials (1)

NCT01845181"First-in-human" Study To Assess the Safety and Tolerability of PBF-680 in Male Healthy Volunteers

Phase 1

PBF-680 5 mg

Asthma

Phase 2

Clinical Trials (1)

NCT01939587Study to Assess the Efficacy of a Single PBF-680 Oral Administration to Attenuate Adenosine 5'-Monophosphate Challenge-induced Airway Hyperresponsiveness in Mild-to-moderate Asthmatics

Phase 2